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Abstract: Some cases of endometrial cancer are associated with a familial tumor and are referred to as hereditary non-
polyposis colorectal cancer (HNPCC or Lynch syndrome). Such tumors are thought to be induced by germline mutation 
of the DNA mismatch repair (MMR) gene, but many aspects of the pathology of familial endometrial cancer are unclear 
and no effective screening method has been established. However, the pathology of endometrial cancer with familial tu-
mor has been progressively clarified in recent studies. At present, about 0.5% of all cases of endometrial cancers meet the 
clinical diagnostic criteria for HNPCC. A recent analysis of the three MMR genes (hMLH1, hMSH2 and hMSH6) revealed 
germline mutations in 18 of 120 cases (15.0%) of endometrial cancer with familial accumulation of cancer or double can-
cer, with a frameshift mutation of the hMSH6 gene being the most common. Many cases with mutation did not meet the 
current clinical diagnostic criteria for HNPCC, indicating that familial endometrial cancer is often not diagnosed as 
HNPCC. The results suggest that the hMSH6 gene mutation may be important in carcinogenesis in endometrial cancer and 
germline mutations of the MMR gene may be more prevalent in cases associated with familial accumulation of cancer. An 
international large-scale muticenter study is required to obtain further information about the pathology of endometrial 
cancer as a familial tumor. 
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INTRODUCTION 
  The incidence of endometrial cancer among malignant 
gynecological tumors has increased with lifestyle and envi-
ronmental changes, and has reached almost half of all cases 
of uterine cancer in Western countries. The absolute number 
and prevalence of cases of endometrial cancer have in-
creased worldwide and control of this cancer is an urgent 
task. However, many aspects of the mechanism of carcino-
genesis and pattern of advancement are unclear. Environ-
mental factors such as obesity and a high estrogen level are 
thought to play important carcinogenic roles, but a close as-
sociation with hereditary disposition has also been sug-
gested, since double cancer and an increased incidence of 
cancer in relatives are common in patients with endometrial 
cancer. 
  A high incidence of concomitant endometrial cancer has 
been shown in female patients with hereditary nonpolyposis 
colorectal cancer (HNPCC), a typical familial tumor that is 
inherited in an autosomal dominant manner, indicating the 
presence of HNPCC-associated familial endometrial cancer. 
HNPCC has a high risk of development of colorectal cancer, 
and accumulation of colorectal cancer in a family line was 
initially reported by Wartin et al. in 1913. Subsequent analy-
sis of this family led Lynch to propose the disease concept  
of cancer family syndrome in 1971 [1, 2]. In 1990, the Inter- 
 
*Address correspondence to this author at the Department of Obstetrics and 
Gynecology, Keio University School of Medicine, Shinanomachi 35 Shin-
juku-ku,Tokyo 160-8582, Japan; Tel: 81-3-3353-1211; Fax: 81-3-3226-
1667; E-mail: kbanno@sc.itc.keio.ac.jp 
national Collaborative Group (ICG)-HNPCC established the 
following clinical diagnostic criteria for HNPCC, which are 
referred to as the classic Amsterdam Criteria: 1) HNPCC is 
diagnosed when 3 or more patients with histologically con-
firmed colorectal cancer are present in a family line and one 
is a first relative of the other two, 2) colorectal cancer devel-
ops over two generations, and 3) one case is diagnosed at 
younger than 50 years old [3]. 
CLINICAL DIAGNOSTIC CRITERIA FOR HNPCC 
  Since the Amsterdam Criteria for HNPCC were proposed 
in 1991, several other diagnostic criteria, including the Japa-
nese Criteria and Bethesda Criteria, have been published. 
The confusion caused by the different criteria was resolved 
by revision of the Amsterdam Criteria by the ICG-HNPCC 
in 1999, to give the new Amsterdam Criteria [4] (Table 1). 
These criteria address endometrial cancer, small intestinal 
cancer, urethral cancer, and kidney cancer, in addition to the 
colorectal cancer included in the classic criteria. Cases not 
meeting the classic Amsterdam Criteria may meet the new 
Amsterdam Criteria, and this has resulted in an increased 
number of cases diagnosed as HNPCC. In addition, discov-
ery of HNPCC has become possible through investigation of 
familial medical histories of endometrial cancer patients. The 
revision also recognized the importance of cooperation 
among gynecologists for identification of HNPCC. One con-
cern with the new criteria is the omission of ovarian, breast 
and stomach cancer, which may also be associated with 
HNPCC.  
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Table 1.  Clinical Diagnostic Criteria for HNPCC  
Amsterdam Minimum Criteria (1990) 
1.   At least 3 cases of colorectal cancer in relatives (verified 
pathologically) 
2.   One is a first degree relative of the other two 
3.   At least two successive generations should be affected 
4.   One case of colorectal cancer diagnosed before the age of  
50 years old 
5.   FAP should be excluded  
Revised Amsterdam Criteria II (1998) 
1.   At least 3 relatives with an HNPCC-associated cancer (cancer 
of the colorectum, endometrium, small bowel, ureter or renal 
pelvis)  
2-5.   As for the minimum criteria 
 
MECHANISM OF HNPCC CARCINOGENESIS AND 
ASSOCIATION WITH ENDOMETRIAL CANCER  
  Six variants of the MMR gene, the causative gene in 
HNPCC, have been cloned: hMSH2, hMLH1, hMSH3, 
hMSH6, hPMS1 and hPMS2. An aberration in one of these 
genes prevents accurate repair of base mismatches produced 
during DNA replication, resulting in production of a DNA 
chain of altered length. This phenomenon is called microsat-
ellite instability (MSI) and can lead to an increased fre-
quency of errors in target genes involved in carcinogenesis, 
resulting in cancerization of the cell. Among the MMR 
genes, germline mutations of hMLH1 on chromosome 3 and 
hMSH2 on chromosome 2 are thought to cause most cases of 
HNPCC, but it is unclear if these mutations are also causa-
tive for HNPCC-associated endometrial cancer. Mutation of 
hMSH6 has also been proposed to be important for develop-
ment of HNPCC-associated endometrial cancer, but the de-
tails are unclear (Fig. 1) [5, 6].  
 The  TGF- type II receptor, which is involved in inhibi-
tion of cell proliferation, and BAX, which is associated with 
apoptosis induction, are candidate target genes in HNPCC 
[7, 8]. The E2F [9], -catenin [10] and TCF-4 [11] genes are 
also candidates, but the frequencies of aberration of these 
genes in endometrial cancer are low. Variation of the target 
gene involved in carcinogenesis in different organs has also 
been suggested. PTEN is also a commonly reported target 
gene in endometrial cancer [12], but its function remains 
unclear. Endometrial cancer develops through a mechanism 
similar to that of HNPCC, but may have unique biological 
characteristics. An analysis of endometrial cancer as a famil-
ial tumor has not been performed and many aspects of the 
cancer are unclear, including its genetic penetrance. 
CLINICAL CHARACTERISTICS OF HNPCC 
  The frequency of HNPCC is unclear due to variation 
among reports, but HNPCC is thought to account for about 
5% of all colorectal cancer cases [13-18] and to have the 
following clinicopathological characteristics: autosomal 
dominant inheritance; genetic penetrance of about 85% at 80 
years of age; development at a young age; frequent devel-
opment in the right colon; often poorly differentiated muci-
nous adenocarcinoma; diploid on cytometric analysis; 
marked intratumor infiltration of lymphocytes; microsatellite 
instability; high risk of development of endometrial cancer, 
urinary tract cancer, and small intestinal cancer; and a favor-
able prognosis [19]. The reason for the favorable prognosis 
despite many cases being poorly differentiated mucinous 
adenocarcinoma is unclear, but may be due to lymphocyte 
infiltration in the tumor and a low rate of lymph node metas-
tasis. An association between aberration of MMR, the causa-
tive gene for HNPCC, and reduced sensitivity to anticancer 
drugs such as cisplatin has also been reported (Fig. 2) [20]. 
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GYNECOLOGICAL CANCERS ASSOCIATED WITH 
HNPCC  
  The close association of endometrial cancer with HNPCC 
is apparent in the new Amsterdam Criteria. However, other 
gynecological cancers have also been reported in the first 
relatives of patients with HNPCC, with the incidence of en-
dometrial cancer being highest at 9-19%, followed by stom-
ach cancer and ovarian cancer at 6-14% and 5-7%, respec-
tively [21]. An association of ovarian cancer with HNPCC 
has been suggested, but may not be as close as that of endo-
metrial cancer, and a link between breast cancer and HNPCC 
has also attracted recent attention. Muir-Torre syndrome is 
an autosomal dominant hereditary disease of concomitant 
sebaceous gland tumors (adenoma, epithelioma and carci-
noma) and malignant visceral tumors, and the incidences of 
colorectal and urogenital cancers are high among malignant 
visceral tumors, followed by breast cancer and malignant 
blood diseases. The lifetime incidence of breast cancer is 
about 12%. Mutation of the hMSH2  MMR gene has been 
found in 2 cases of Muir-Torre syndrome [22, 23] and this 
disease is assumed to have the pathology of hereditary breast 
cancer and to be a subtype of HNPCC. 
ENDOMETRIAL CANCER AND MICOSATELLITE 
INSTABILITY (MSI) 
  To investigate the status and clinicopathological charac-
teristics of familial endometrial cancer, Banno et al. [24] 
surveyed the familial and medical histories of 385 patients 
who underwent treatment for endometrial cancer. MSI 
analysis was performed in 38 of these patients. The familial 
medical histories showed that 2 of the 385 cases met the new 
Amsterdam Criteria for HNPCC, giving a rate of HNPCC of 
about 0.5%. Investigation of familial accumulation of cancer 
in 890 relatives (439 men and 451 women) of the 38 endo-
metrial cancer patients who underwent MSI analysis re-
vealed high incidences of endometrial cancer, colorectal 
cancer and ovarian cancer, suggesting that a hereditary factor 
common to HNPCC is also involved in endometrial cancer. 
MSI analysis detected the presence of at least one of 5 mi-
crosatellite markers (D2S123, D3S1284, D5S404, D9S162, 
and hMSH2 intron 12) in 12 of the 38 cases (31.6%). This 
rate is very high compared to MSI in cancers of other organs, 
demonstrating that abnormal DNA mismatch repair plays an 
important role in endometrial cancer. The patients with MSI 
showed a tendency to have double cancer (such as ovarian 
cancer) compared with patients with microsatellite stability 
(MSS), although the difference was not significant (27% vs. 
15%). Regarding prognosis, none of the MSI-positive cases 
were fatal (0/11, 0%), while 5 MSI-negative (MSS) cases 
were fatal (5/27, 19%). The difference was not significant, 
but this tendency is similar to that for HNPCC-associated 
colorectal cancer. The incidences of moderately differenti-
ated adenocarcinoma G2 (36%) and poorly differentiated 
adenocarcinoma G3 (18%) tended to be higher in MSI-
positive endometrial cancer, although the difference was not 
significant. These findings appear contradictory with the 
favorable prognosis, but interestingly they may reflect the 
biological characteristics of endometrial cancer induced by 
abnormal DNA mismatch repair [25]. 
GERMLINE MUTATIONS IN ENDOMETRIAL CAN-
CER PATIENTS WITH FAMILIAL ACCUMULATION 
OF CANCER  
 Hirai  et al. [26] have recently performed an analysis of 
germline mutation of three MMR genes (hMLH1, hMSH2 
and hMSH6) in 120 patients with endometrial cancer with 
strongly hereditary familial cancer accumulation or double 
cancer. Cases in which two or more first relatives had 
HNPCC-associated tumors (colorectal, endometrial, small 
intestinal, urethral, and renal pelvic cancers) and stomach, 
ovarian and breast cancers were designated as Group A, and 
cases with synchronous or metachronous double cancer of 
HNPCC-associated tumors (colorectal, endometrial, small 
intestinal, urethral and renal pelvic cancers) with stomach, 
ovarian or breast cancer were designated as Group B. Of the 
120 cases, 57 were in Group A and 48 in Group B, with 15 
in both groups. White blood cell-derived DNA was obtained 
from the patients and germline mutations were analyzed by 
direct sequencing of PCR products amplified using primers 
for all exons of hMLH1, hMSH2 and hMSH6. Germline mu-
tation of the MMR genes was detected in 18 of the 120 cases 
(15.0%), including 9 of the 57 cases (15.8%) in Group A and 
4 of the 48 cases (8.3%) in Group B. A high rate of germline 
mutation of MMR genes (5/15, 33.3%) was found in cases 
meeting the criteria for both groups. Mutations were detected 
in the hMSH6 gene in 9 cases (50%), the hMLH1 gene in 5, 
and the hMSH2 gene in 4. Mutations of the hMSH6 gene 
were concentrated in regions near exons 4-5 and were 
frameshifts in most cases. The mutations in 7 of the 18 cases 
had already been reported in the literature and registered in a 
mutation database, but those in the other 11 cases had not 
been reported previously [26] (Table 2).  
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SCREENING OF ENDOMETRIAL CANCER AS 
HNPCC 
  The clinical characteristics of HNPCC in colorectal can-
cer have gradually been clarified and HNPCC is thought to 
account for about 5% of all colorectal cancer cases. In con-
trast, there are only a few reports on endometrial cancer, 
despite its similar association with MMR gene aberration. 
An interview of families of 385 patients with endometrial 
cancer designed to investigate the familial medical histories 
of cancer revealed 2 patients who met the clinical diagnostic 
criteria for HNPCC [24]. This indicates that only 0.5% of all 
endometrial cancer cases are diagnosed as HNPCC, and this 
rate is markedly lower than that in colorectal cancer.  
  Microsatellite instability caused by MMR gene aberra-
tion is detectable by PCR using microsatellite markers. In 
screening for HNPCC, use of 5 microsatellite markers 
(BAT25, BAT26, D5S346, D2S123 and D17S250) is rec-
ommended. However, a germline mutation of the MMR gene 
was detected in only 1 of 12 patients with MSI-positive en-
dometrial cancer (8.3%) and this mutation was a nonsense 
mutation at codon 100 of the hMLH1 gene. This mutation 
was already registered as a functional gene mutation in the 
Human Gene Mutation Database (HGMD), but this case did 
not meet the new Amsterdam Criteria for HNPCC [26]. This 
suggests that current clinical diagnostic criteria and MSI 
analysis have limited value in screening for HNPCC-
associated endometrial cancer. 
 In  Hirai  et al. [26], germline mutation of the MMR gene 
was present in 15.8% of patients with endometrial cancer 
with familial accumulation of cancer, but not meeting the 
clinical diagnostic criteria for HNPCC. This suggests that 
MMR gene aberration should be kept in mind in manage-
ment of patients with a tendency for familial cancer, regard-
less of the clinical assessment. In particular, familial devel-
opment of breast, ovarian and stomach cancer, which are not 
recognized as HNPCC-associated cancers, should be investi-
gated in interviews on familial medical histories. No germ-
line mutation of the MMR gene was present in cases with 
double cancer alone without familial cancer accumulation, 
but all double cancers developed earlier than endometrial 
cancer, which is very interesting from the perspective of 
screening for endometrial cancer. 
 The  hMSH6 gene was the most commonly mutated 
MMR gene found by Hirai et al. [26], rather than hMLH1 or 
hMSH2, which are frequently mutated in colorectal cancer. 
This finding indicates the importance of hMSH6 in develop-
ment of endometrial cancer in HNPCC, and suggests an as-
sociation between the MMR genotype and the cancer pheno-
type. Most interestingly, the mutations of hMSH6 were con-
centrated in exons 4-5 and were frameshifts. One of the 
Table 2.  Eighteen Patients with Endometrial Cancer had MMR Gene Mutations in Germ Cells 
No.   Age   Type   Grade   Stage   Group   Mutation Type   Report   Double Cancer 
K007   42   EM/CL   G2   3c   AB   hMLH1 ex3 codon100 Nonsense   +   CC(42yo) 
K009   42   EM   G1   1b   A   hMSH6 ex5 codon1085 Frameshift   +    
K017   34   EM   G2   1b   A   hMSH2 ex10 codon554 Missense       
K023   56   EM   G1   1a   A   hMSH6 ex4 codon795 Frameshift       
K030   52   EM   G2   3a   A   hMSH6 ex4 codon546 Frameshift       
K031   54   EM   G2   1a   A   hMSH2 ex11 codon582 Frameshift       
T004   56   EM   G1   3a   A HNPCC  hMSH2 ex13 codon680 Nonsense  +   
T011   65   AS   G1   3a   B   hMSH6 ex6 codon1163 Missense      BC(65yo) 
T016   41   EM   G1   1b   AB HNPCC   hMSH2 ex5 codon288 Nonsense   +   CC(38,50yo) 
J001   48   EM   G1   1b   AB HNPCC   hMLH1 ex16 codon618 Deletion   +   CC(44yo) 
J015   53   EM   G1   1a   B   hMSH6 ex4 codon744 Frameshift      OvC(53yo) 
J021   55   EM   G1   1b   A   hMSH6 ex4 codon482 Nonsense       
G001   52   EM   G1   3c   AB HNPCC   hMLH1 ex13 Splicing   +   CC(48,50yo) 
G030   57   EM   G2   1b   B   hMSH6 ex10 codon1355 Frameshift      BC(39yo) 
G032   62   EM   G3   1a   A   hMSH6 ex4 codon487 Frameshift       
G036   50   EM   G1   1a   A   hMSH6 ex4 codon742 Missense       
F001   37   EM   G1   1a   B   hMLH1 ex12 codon384 Missense      CC(36yo) 
F002   46   EM   G1   1b   AB   hMLH1 ex16 codon618 Deletion   +   CC(46yo) 
CC: Colorectal Cancer, BC: Breast Cancer, OvC: Ovarian Cancer. Endometrial Cancer as a Familial Tumor  Current Genomics, 2009, Vol. 10, No. 2    131 
hMSH6 mutations was a reported functional mutation, but 
the concentration in exons 4-5 differed from reports in West-
ern patients. Thus, it is possible that this gene mutation is 
characteristic for HNPCC-associated endometrial cancer 
(Table 3) [27, 28].  
FUTURE DIRECTIONS AND CONCLUSION 
  Many HNPCC-associated cases of endometrial cancer 
caused by MMR gene aberration do not meet the current 
clinical diagnostic criteria for HNPCC. Gene analysis focus-
ing on the hMSH6 gene may allow efficient identification of 
familial endometrial cancer in cases of endometrial cancer 
with a tendency of familial accumulation of cancer. The 
findings that some cases of endometrial cancer are familial 
tumors and that an abnormal DNA mismatch repair gene is 
linked to development of the cancer are important for under-
standing the biological characteristics of endometrial cancer. 
Thus, it is important to identify and analyze patients with 
this type of endometrial cancer. However, cases of familial 
endometrial cancer that meet the current diagnostic criteria 
account for only 0.5% of all cases, and a close examination 
of family history is essential in screening for this cancer. An 
improved understanding of familial tumors among gyne-
cologists and an international large-scale muticenter study 
are required for further progress, with establishment of a 
system of genetic tests and counseling for patients. There are 
currently many aspects of familial endometrial cancer that 
are unclear, but clarification of the pathology and develop-
ment of a surveillance system and genetic tests are likely to 
produce new diagnostic and therapeutic methods for various 
types of endometrial cancer. 
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